This work was supported by grant POIG 01.01.02-00-109/09.
No CrossRef data available.
Our systems are now restored following recent technical disruption, and we’re working hard to catch up on publishing. We apologise for the inconvenience caused. Find out more: https://www.cambridge.org/universitypress/about-us/news-and-blogs/cambridge-university-press-publishing-update-following-technical-disruption
Published online by Cambridge University Press: 15 April 2020
in this study, we tested the novel hypothesis that stem cells and those factors that modulate their trafficking may be biological markers for acute psychosis.
Twenty-eight subjects during their first nonaffective psychotic episode were investigated before and after antipsychotic treatment and were compared with 35 healthy controls (CG); the psychotic group (PG) was divided into ‘schizophrenic’ (SG) and ‘non-schizophrenic’ (NG) subgroups.
We examined the number of circulating Lin–/CD45−/CD34+ and Lin–/CD45−/CD133+ very small embryonic-like stem cells (VSELs), which express markers of the neural lineage, and also the plasma levels of factors that modulate their trafficking: the C3a, C5a, and C5b-9 activated complement cascade components, stromal-derived factor 1, and sphingosine-1-phosphate (S1P).
We found that the mean numbers of Lin–/CD45−/CD34+ VSELs and the plasma levels of S1P prior to treatment differ between the CG and PG and that these cells express markers of neural lineage. The number of Lin–/CD45−/CD133+ VSELs in peripheral blood differed between the SG and NG prior to treatment.
we found that C3a and S1P are the best predictors of risk and are potential markers for the first psychotic episode. Furthermore, in the SG, the number of circulating Lin–/CD45−/CD34+ VSELs and the S1P plasma level are the best predictors of risk and are proposed as novel markers for the first ‘schizophrenic’ episode of psychosis.
This work was supported by grant POIG 01.01.02-00-109/09.
Comments
No Comments have been published for this article.